Consumer Goods Registry: Over-The-Counter Pharmaceuticals
About 1,500 companies manufacture and market medical drugs with combined annual revenue of more than $200 billion, but this list shines a spotlight on the top 5 pharmaceutical companies that lead the charge in consumer healthcare with popular over-the-counter brands.
| COMPANY | 2007 SALES (millions) | YEARLY SALES GROWTH | BRANDS | |
| 1 | Johnson & Johnson (Consumer Segment) | $14,493 | 48% | BAND-AID, Neosporin, Tylenol |
| 2 | GlaxoSmithKline (Consumer Segment) | $6,049* | 11% | Lucozade, Aquafresh, Sensodyne |
| 3 | Novartis (Consumer Health Division) | $5,426 | 11% | CIBA Vision, Excedrin, Theraflu |
| 4 | Bayer Healthcare (Consumer Care) | $3,599* | 4% | Alka-Seltzer Plus, Bayer Aspirin, Midol |
| 5 | Wyeth (Consumer Healthcare) | $2,736 | 8% | Advil, Centrum, Dimetapp |
* Denotes live exchange rates on Oct. 9, 2008
OTC Pharmaceutical News
1. Johnson & Johnson (consumer segment)
Johnson & Johnson's consumer health care businesses delivered 48 percent growth in 2007 in the midst of a massive integration of Pfizer Consumer Health that extended its U.S. leadership from 13 to 22 categories. Overall, this segment accounted for 24 percent of Johnson & Johnson's total sales in 2007, which equaled $61.1 billion. In line with its continued focus on bringing people innovative, science-based products with clinically proven benefits, Johnson & Johnson's consumer health care segment launched approximately 600 new products and line extensions in 2007, including the Neutrogena Anti-Oxidant Age Reverse line, the Band-Aid Activ-Flex Blister Block Stick and Listerine Whitening Quick Dissolving Strips. In December 2007, the company opened a new Consumer R&D Center in Shanghai, which is dedicated to developing even more innovative products for emerging markets around the world.
3. Novartis (consumer Health Division)
September 2007 saw the completed sale of the Gerber baby foods business by Novartis to Nestle for $5.5 billion, the final step in a divestment program to focus Novartis' strategy on healthcare with pharmaceuticals at the core. In 2008, Novartis reached another agreement with Nestle S.A. to acquire majority ownership of Alcon Inc. in two steps, and add the world leader in eye care to its diversified portfolio. Novartis also recently announced that its "Forward" initiative, which aims to enhance productivity by streamlining the organization and redesigning the way it operates, was progressing well since its launch in December 2007. In the Consumer Health Division, the initiative involves the removal of organizational layers to streamline processes and eliminate duplications. In addition, some product supply chains will be restructured to optimize capacity utilization. By the first half of 2008, Novartis announced that about 65 percent of the anticipated 2008 cost savings of the projected $670 million have been delivered. At that time, the reduction of 2,500 full-time equivalent positions as also underway.
OTC Pharmaceutical News
1. Johnson & Johnson (consumer segment)
Johnson & Johnson's consumer health care businesses delivered 48 percent growth in 2007 in the midst of a massive integration of Pfizer Consumer Health that extended its U.S. leadership from 13 to 22 categories. Overall, this segment accounted for 24 percent of Johnson & Johnson's total sales in 2007, which equaled $61.1 billion. In line with its continued focus on bringing people innovative, science-based products with clinically proven benefits, Johnson & Johnson's consumer health care segment launched approximately 600 new products and line extensions in 2007, including the Neutrogena Anti-Oxidant Age Reverse line, the Band-Aid Activ-Flex Blister Block Stick and Listerine Whitening Quick Dissolving Strips. In December 2007, the company opened a new Consumer R&D Center in Shanghai, which is dedicated to developing even more innovative products for emerging markets around the world.
3. Novartis (consumer Health Division)
September 2007 saw the completed sale of the Gerber baby foods business by Novartis to Nestle for $5.5 billion, the final step in a divestment program to focus Novartis' strategy on healthcare with pharmaceuticals at the core. In 2008, Novartis reached another agreement with Nestle S.A. to acquire majority ownership of Alcon Inc. in two steps, and add the world leader in eye care to its diversified portfolio. Novartis also recently announced that its "Forward" initiative, which aims to enhance productivity by streamlining the organization and redesigning the way it operates, was progressing well since its launch in December 2007. In the Consumer Health Division, the initiative involves the removal of organizational layers to streamline processes and eliminate duplications. In addition, some product supply chains will be restructured to optimize capacity utilization. By the first half of 2008, Novartis announced that about 65 percent of the anticipated 2008 cost savings of the projected $670 million have been delivered. At that time, the reduction of 2,500 full-time equivalent positions as also underway.